Patrick Girondi Sues Biotech and Venture Capitalist Firm over charges of violating RICO Act

A civil action has been filed, charging violations of the Federal Racketeering and Corrupt Organizations Act (RICO), fraudulent inducement and unfair business practices in the United States District Court in Massachusetts. The defendants are Nick Leschly, Mitchell Finer, Phillip Reilly, Third Rock Ventures, bluebird bio Inc., and 2seventy Bio Inc. This lawsuit is linked to the TrialSite’s ongoing tracking of the San Rocco Therapeutics (SRT), formerly Errant Gene Therapeutics, and bluebird legal conflict. See “A FamilyMan’s battle against the forefront of capitalist medicine: the case of Errant Gene Therapeutics.”

Nick Leschly, the former CEO of bluebird bio, profited $24,000,000, alone in 2018, making him the highest compensated pharma CEO in the world. The complaint alleges that his earnings were a direct result of fraudulent and corrupt RICO violations at the expense of the health of patients. Bluebird bio’s gene therapy was approved in August 2022 to treat Thalassemia for $2.8 million per patient. SRT has a safer gene therapy product that will cost over $2,000,000 less at $700,000.
------------------------------------
Join The Conversation! | https://trialsitenews.com/